May 8 Cobalt International Energy Inc-
* Cobalt International Energy Inc announces first quarter 2017 results and provides operational update
* Q1 loss per share $0.69
* Q1 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S
* Cobalt International Energy - expect capital expenditures to be about $250 million in 2017, which excludes general,administrative expenses,interest expense
* Cobalt International Energy- total 2017 cash outlays currently expected to be between $550 million and $600 million, of which about $196 million has been spent as of march 31, 2017 Source text for Eikon: Further company coverage:
Novartis gets European OK for biosimilar of Amgen's Enbrel
ZURICH, June 27 Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.